Motivational intervention to reduce benzodiazepine use in chronic drug users
Official title: Impact of Identification and Brief Motivational Intervention in Dispensing Pharmacies (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
Run by University Hospital, Grenoble · NCT06446349 · Data updated 2026-11-12
This study is testing whether a short motivational talk from pharmacists can help adults who have been using benzodiazepines for a long time reduce their medication dosage and improve their health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 20 sites (Annonay and 19 other locations) |
| Status | Recruiting |
| Started | December 3, 2024 |
| Main results expected | April 3, 2027 |
| Study ends | April 3, 2027 |
| Registry record updated | October 2, 2026 |
| Trial ID | NCT06446349 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults who have been on continuous treatment with benzodiazepines or related substances for at least six months.
✕Probably not a fit
Patients currently undergoing treatment with certain antipsychotics, mood stabilizers, or those with a history of severe withdrawal symptoms may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This intervention aims to evaluate the effectiveness of a brief motivational intervention (BMI) conducted by pharmacists to reduce the daily dosage of benzodiazepines and related substances (BZD/Z) in adult patients who have been using these medications for at least six months. The study will assess the impact of BMI on both the reduction of prescribed doses and the clinical outcomes of patients over a six-month period. The approach involves comparing the outcomes of patients receiving the BMI against those receiving standard dispensing practices in pharmacies. The study is set in France, where the prevalence of long-term BZD/Z prescriptions is a growing concern.
Why it matters
Potential benefit: If successful, this intervention could lead to safer prescribing practices and improved health outcomes for patients dependent on benzodiazepines.
How similar studies have gone: While the approach of using motivational interventions in pharmacy settings is promising, this specific application to benzodiazepine deprescribing is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Continuous treatment (at least once daily) with BZD/Z for at least 6 months, after verification of 6 months' supply. * Signed informed consent * Patient able to understand the survey and complete a questionnaire in French. * Affiliation with the French social security system Exclusion Criteria: * Concomitant treatment with: * The following oral antipsychotics: risperidone, olanzapine, aripiprazole, quetiapine, clozapine, haloperidol, flupentixol, pimozide, chlorpromazine, sulpiride, zuclopenthixol, loxapine, cyamemazine (\>100mg/D), sulpiride (\>150mg/D), * Injectable medium- and long-acting antipsychotics * Thymoregulatory treatment with lithium * Treatments for alcohol use disorders: baclofen, nalmefene, naltrexone, acamprosate, disulfiram * Opiate substitution treatments: buprenorphine, methadone * Anti-epileptic drugs * History of convulsions or epilepsy * History of gabaergic withdrawal accidents: delirium tremens, confusional syndrome requiring specialist treatment (hospitalisation, specialist consultation), epileptic seizures, etc. * Patients suffering from cancer * Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons: pregnant women, women in childbirth, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).
Where it's running
-
Pharmacie Riffard Annonay
Annonay, France Recruiting -
Pharmacie du Village
Auriol, France Recruiting -
Pharmacie des Champs Dolent
Beauvais, France Recruiting -
Pharmacie Troisgros
Cap-d'Ail, France Recruiting -
Pharmacie des Fontanilles
Castelnaudary, France Recruiting -
Pharmacie Dolus d'Oléron
Dolus-d'Oléron, France Recruiting
Show 14 more locations
-
Pharmacie de Dommartin
Dommartin, France Recruiting -
Pharmacie du Mont Guillaume
Embrun, France Recruiting -
Ma Pharmacie Evenos
Évenos, France Recruiting -
Pharmacie du Pog
Lavelanet, France Recruiting -
Pharmacie de Lentilly
Lentilly, France Recruiting -
Pharmacie Thomas
Ludres, France Recruiting -
Pharmacie Saint Pierre Marignane
Marignane, France Recruiting -
Pharmacie Milan Saint-Giniez
Marseille, France Recruiting -
Pharmacie de la Sèvre
Moncoutant, France Recruiting -
Pharmacie de St georges
Saint-Georges-de-Reineins, France Recruiting -
Pharmacie du Théâtre
Saint-Omer, France Recruiting -
Pharmacie du Château
Saint-Porchaire, France Recruiting -
Pharmacie Labarrière
Savigné-l'Évêque, France Recruiting -
Pharmacie de l'Ermitage
Villemoisson-sur-Orge, France Recruiting
Study contacts
- Principal investigator: Lucie PENNEL, MD,PhD — University Hospital, Grenoble
- Study coordinator: Lucie Pennel, MD, PhD
- Email: LPennel@chu-grenoble.fr
- Phone: +33 670 386 149
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.